New steroids for IBD: progress report

New steroids for IBD: progress report.

Corticosteroids remain the benchmark therapy for moderate to severe ulcerative colitis and Crohn’s disease but are problematic due to unacceptable side effects and lack of maintenance benefits. Developments in corticosteroid chemistry have led to a series of antiinflammatory glucocorticoids with enhanced topical (mucosal) potency and less systemic activity such as prednisolone-metasulphobenzoat...

New IBD genes?

C rohn’s disease (CD) and ulcerative colitis result from an inappropriate response of the mucosal immune system to the normal enteric flora in a genetically susceptible individual. The importance of genetic predisposition was firmly established in 2001 by the identification of the first CD susceptibility gene NOD2 (CARD15) on chromosome 16q12 (IBD1). 2 It is now clear that NOD2 variants contrib...

Combating the New Plagiarism: A Progress Report

The many positive features of the Internet ,with regard to student learning, have a downside that it enables the “new plagiarist “ to almost effortlessly copy enormous quantities of unacknowledged text. Recent developments in the UK which attempt to address this problem are reported with reference to a postgraduate research skills module that is offered at the University of Sunderland. Details ...

MicroRNAs: new players in IBD

MicroRNAs (miRNAs) are small non-coding RNAs, 18-23 nucleotides long, which act as post-transcriptional regulators of gene expression. miRNAs are strongly implicated in the pathogenesis of many common diseases, including IBDs. This review aims to outline the history, biogenesis and regulation of miRNAs. The role of miRNAs in the development and regulation of the innate and adaptive immune syste...

Toward Progress Indicators on Steroids for Big Data Systems